425: RadNet to Acquire iCAD in Stock-for-Stock Deal, Expanding AI Capabilities in Breast Imaging

RadNet is set to acquire iCAD in a stock-for-stock transaction, aiming to bolster its artificial intelligence capabilities in breast imaging and expand its market reach.

Summary

• RadNet announced the acquisition of iCAD in a stock-for-stock deal, valuing iCAD's equity at $103 million based on RadNet's closing price on April 15, 2025.
• The acquisition aims to combine RadNet's DeepHealth AI breast imaging tools with iCAD's AI technology, creating a more comprehensive portfolio of breast imaging AI solutions.
• RadNet anticipates a positive Adjusted EBITDA run rate by the end of 2026 following the acquisition, driven by over $7 million in run rate cost synergies.
• The combined entity will have access to approximately 10 million annual mammograms across over 1,700 provider sites in more than 50 countries.
• The transaction is expected to close during the second or third quarter of 2025, subject to iCAD stockholder approval and customary closing conditions.
• RadNet's Digital Health division expects revenue of $80 million to $90 million and Adjusted EBITDA of $15 million to $17 million in 2025.
• iCAD's 2024 revenue was approximately $20 million, and the acquisition is expected to add $4 million to $5 million to RadNet's 2025 revenue, with a neutral impact on EBITDA.
• The acquisition will bring 66 iCAD employees into the DeepHealth family, strengthening commercial, product, and R&D teams.

Sentiment

Score: 8

Explanation: The document expresses a positive outlook on the acquisition, highlighting the strategic benefits, synergies, and growth opportunities. Management conveys enthusiasm and confidence in the combined entity's future prospects.

Positives

• The acquisition creates a more comprehensive portfolio of breast imaging AI solutions.
• It expands RadNet's reach to a larger customer base and geographic footprint.
• The deal is expected to generate cost synergies and improve financial performance.
• The acquisition brings experienced professionals to RadNet's Digital Health team.
• It accelerates RadNet's growth plans and expands its capabilities in AI.

Negatives

• iCAD had an EBITDA loss of approximately $4 million in 2024.
• The transaction is subject to stockholder approval and customary closing conditions, which could delay or prevent the acquisition.
• Integration of iCAD into RadNet's business may present challenges.

Risks

• The inability to obtain iCAD stockholder approval or satisfy other closing conditions could prevent the transaction.
• Failure to achieve the anticipated synergies or successfully integrate iCAD could negatively impact financial performance.
• Legislative, regulatory, economic, competitive, and technological changes could affect the combined company.
• The value of RadNet's securities issued in the merger could fluctuate.
• Litigation related to the proposed transaction could arise.

Future Outlook

RadNet expects the acquisition to enhance its financial performance, with a positive Adjusted EBITDA run rate by the end of 2026. The company also anticipates further developments in the ultrasound and x-ray space.

Management Comments

• Dr. Berger stated that the acquisition demonstrates RadNet's commitment to leading radiology forward.
• Dr. Sorensen highlighted the potential to improve the lives of women through screening technologies.
• Kees Wesdorp emphasized the strategic reasons for the acquisition: skill and capabilities, customer reach, and the most comprehensive portfolio of breast imaging AI solutions.
• Sanjog Misra noted that the addition of the iCAD team will accelerate RadNet's growth plans and expand its capabilities at DeepHealth.
• Sham Sokka discussed the complementary progressive set of offerings for customers early in their AI adoption journey.

Industry Context

The acquisition reflects a trend of consolidation in the AI industry within radiology, as companies seek to establish themselves as viable players and continue to invest in their AI offerings. RadNet aims to be a leader in artificial intelligence for mammography, ultrasound, and x-ray.

Comparison to Industry Standards

• RadNet's Enhanced Breast Cancer Detection program has shown a more than 20% boost in cancer detection rate.
• RadNet performs approximately 2 million mammograms a year, which is about as many as the entire country of England.
• iCAD's software is used by more than 1,500 healthcare providers in over 50 countries.
• The combined entity will have access to approximately 10 million annual mammograms, four times as many as RadNet currently touches.

Stakeholder Impact

• Shareholders of iCAD will receive RadNet stock in exchange for their shares.
• Employees of iCAD will become part of the DeepHealth team.
• Customers of both RadNet and iCAD will have access to a broader range of AI solutions.
• Patients will benefit from improved breast cancer detection and screening technologies.

Next Steps

• iCAD will mail a proxy statement/prospectus to its stockholders.
• iCAD stockholders will vote on the proposed transaction.
• RadNet and iCAD will work to satisfy customary closing conditions.
• RadNet will integrate iCAD into its business.

Key Dates

Keywords

RadNet, iCAD, acquisition, artificial intelligence, breast imaging, DeepHealth, mammography, synergies, EBITDA, digital health